Clinical trial
An Open-label, Single-arm, and Multicenter Phase Ⅱ Study to Evaluate the Efficacay and Safety of F520 Combined With F007 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
NCT05178836 is registered in ClinicalTrials.gov with Shandong New Time Pharmaceutical Co., LTD as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Single-arm, and Multicenter Phase Ⅱ Study to Evaluate the Efficacay and Safety of F520 Combined With F007 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
- Lead sponsor
- Shandong New Time Pharmaceutical Co., LTD
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- January 1, 2022
- Completion date
- December 31, 2023
- Enrollment
- 62 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
rr dlbcl; pd-1; cd20